NCT05836948View on ClinicalTrials.gov

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

May 18, 2023

Primary Completion Date

May 1, 2026

Study Completion Date

June 1, 2026

Conditions

Advanced Solid Tumor

Interventions

DRUG

SHR-9839

Weekly fixed dose injection of SHR-9839

Trial Locations (1)

310006

RECRUITING

Zhejiang Tumor Hospital, Hangzhou

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY